Nifedipine Versus Atosiban for Threatened Preterm Birth (APOSTEL III): A Multicenter, Randomized Controlled Trial. Issue 9 (September 2016)

• Record Type: Journal Article
• Authors: van Vliet, Elvira O. G.; Nijman, Tobias A. J.; Schuit, Ewoud; Heida, Karst Y.; Opmeer, Brent C.; Kok, Marjolein; Gyselaers, Wilfried; Porath, Martina M.; Woiski, Mallory; Bax, Caroline J.; Bloemenkamp, Kitty W. M.; Scheepers, Hubertina C. J.; Jacquemyn, Yves; van Beek, Erik; Duvekot, Johannes J.; Franssen, Maureen T. M.; Papatsonis, Dimitri N.; Kok, Joke H.; van der Post, Joris A. M.; Franx, Arie; Mol, Ben W.; Oudijk, Martijn A.
• Is Part Of: Obstetrical & gynecological survey. Volume 71:Issue 9(2016)
• Publication Date: 2016-09
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000491261.80068.f8
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from Lancet 2016;387:2117–2124) Preterm birth is estimated to affect between 5% and 13% of all pregnancies and is the reason for more than 50% of neonatal morbidity and 50% and 75% of neonatal mortality cases worldwide. It causes long-term physical and developmental impairment, thus having a substantial burden on families and health care costs.